Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS)

Recruiting

Phase 2

TezepelumabTezepelumab in Allergic Rhinitis and Asthma Study (TEZARS)

Sponsor:

Dr. Anne Ellis

Code:

NCT06189742

Conditions

Asthma With Allergic Rhinitis

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

Tezepelumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-22. This information was provided to ClinicalTrials.gov by Dr. Anne Ellis on 2024-06-27.